Synribo

Active Ingredient(s): Omacetaxine Mepesuccinate
FDA Approved: * October 26, 2012
Pharm Company: * IVAX PHARMS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Synribo Overview

Omacetaxine mepesuccinate (INN, trade names Synribo ), formerly named as homoharringtonine or HHT, is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML). HHT is a natural plant alkaloid derived from Cephalotoxus fortune. HHT and related compound esters of cephalotaxine were described first in 1970, and were the subject of intensive research efforts by Chinese investigators to clarify their role as anticancer and antileukemic agents from the 1970s...

Read more Synribo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Omacetaxine_mepesuccinate

Recent Synribo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Synribo: (1 result)

Sorted by National Drug Code

• 63459-177 Synribo 3.5 mg/ml Subcutaneous Injection, Powder, Lyophilized, for Solution by Cephalon, Inc.

Other drugs which contain Omacetaxine Mepesuccinate or a similar ingredient: (1 result)

• OMACETAXINE MEPESUCCINATE

Related Synribo Topics: